Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer

Exclusion Criteria

• •Prior treatment with any investigational drug within the previous 4 weeks
• •Chronic treatment with systemic steroids or another immunosuppressive agent
• •Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
• •Patients who have a history of another primary malignancy ≤ 3 years, with the exceptions of non-melanoma skin cancer, and carcinoma in situ of uterine cervix
• •Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study
• •A known history of HIV seropositivity
• •Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)
• •Patients with an active, bleeding diathesis or on oral anti-vitamin K medication
• •Women who are pregnant or breast feeding, or women/men able to conceive and unwilling to practice an effective method of birth control from enrollment through 6 months following the end of treatment
• •Patients who have received prior treatment with an mTOR inhibitor.
• •Patients with a known hypersensitivity to RAD001 (everolimus) or other rapamycins (sirolimus, temsirolimus) or to its excipients
• •History of noncompliance to medical regimens
• •Patients unwilling to or unable to comply with the protocol